Information Note
Advice for countries using or planning
to introduce dual HIV/syphilis RDT in antenatal services and other testing sites.
WHO/RHR/17.01
Prepared for the Stunting Prevention and Reduction Project - The project Medical Waste Management Plan’s (MWMP) overall objective is to prevent and/or mitigate the negative effects of increased generation of medical waste on human health and the environment. The plan proposes measures to prevent t...he spread of infection and reduce the
exposure of health workers, patients and the general public to the risks from medical waste. The plan is to be used by all project implementation entities to manage medical waste associated with
project activities. These entities will have appropriate procedures and capacities in place to manage the medical waste.
more
Externalizing disorders
Chapter 1.1
Since the beginning of December a significant increase in the incidence of new cases has been observed particularly along the corridor towards the large urban center of Butembo (health zones of Butembo and Katwa) and beyond in the zone of Kayna health center located about 150 km from Goma. In additi...on, active outbreaks have emerged to the north, particularly in the health zones of Komanda and Oicha.
The third strategic response plan (SRP-3), which covers February through end July 2019, considers the salient points and recommendations made during the operational review of the implementation of the SRP-2 and other guidance based on lessons learned and risk analysis.
more
This action plan for the Kingdom Saudi Arabia to combat antimicrobial resistance has been formulated in the line of the WHO five objectives. It addresses the need for effective “one health” approach involving coordination among numerous national sectors and actors, including human and veterinary... medicine, agriculture, finance, environment, and well-informed consumers. Therefore, a large committee of all stakeholders was formed with five technical subcommittees were established to addresses every aspect
to contain antimicrobial resistance in the country.
more
Qualitative assay for use on the cobas®6800/8800 Systems. For in vitro diagnostic use
Scientific brief
8 April 2020
Drug registration in Kenya started in 1982; the process mainly involves an evaluation committee at the Kenya Pharmacy and Poisons Board (PPB) that aims to approve products based on quality, safety and efficacy.